Natural Products from Schisandra chinensis
Natural Products Isolated from Schisandra chinensis
BioCrick provides high-purity natural products and bioactive compounds isolated and purified from natural sources for scientific research.
- Natural product compounds selected from diverse chemical and biological sources.
- Broad structural diversity and coverage of biological activities.
- Product activity information can be supported by published literature, patents and research reports.
- Natural products can be selected according to source, target, activity and disease research interests.
- Compounds should be stored according to the product specifications after receipt.
Natural Products from Schisandra chinensis
34 natural product s associated with Schisandra chinensis
| Catalog No. | Product Name | CAS Number | COA |
|---|---|---|---|
| BCN2863 |
(-)-Holostyligone
|
887501-28-2 | COA |
| BCN4537 |
3,4-Dihydroxybenzoic acid
|
99-50-3 | COA |
| BCN2843 |
Angeloylgomisin H
|
66056-22-2 | COA |
| BCN7361 |
Angeloylgomisin O
|
83864-69-1 | COA |
| BCN5362 |
Anwulignan
|
107534-93-0 | COA |
| BCN5979 |
Caffeic acid
|
331-39-5 | COA |
| BCN7847 |
Chamigrenal
|
19912-84-6 | COA |
| BCN7818 |
Chicanine
|
78919-28-5 | COA |
| BCN1029 |
D-(-)-Quinic acid
|
77-95-2 | COA |
| BCN5590 |
Daidzein
|
486-66-8 | COA |
| BCN1240 |
Dehydrodiisoeugenol
|
2680-81-1 | COA |
| BCN5794 |
Gomisin A
|
58546-54-6 | COA |
| BCN2268 |
Gomisin D
|
60546-10-3 | COA |
| BCN2269 |
Gomisin G
|
62956-48-3 | COA |
| BCN3902 |
Gomisin H
|
66056-20-0 | COA |
| BCN2270 |
Gomisin J
|
66280-25-9 | COA |
| BCN2875 |
Gomisin O
|
72960-22-6 | COA |
| BCX0642 |
Isokadsuranin
|
82467-52-5 | COA |
| BCN8390 |
Myristic acid
|
544-63-8 | COA |
| BCN2674 |
Negsehisandrin G
|
1023744-69-5 | COA |
| BCN2851 |
Quercetin 3-O-beta-D-xylopyranoside
|
549-32-6 | COA |
| BCN1521 |
rel-(8R,8'R)-dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan
|
178740-32-4 | COA |
| BCN5815 |
Schisandrin A
|
7432-28-2 | COA |
| BCN1198 |
Schisandrin C
|
61301-33-5 | COA |
| BCN3316 |
Schisandrone
|
98619-25-1 | COA |
| BCN2508 |
Schisanhenol
|
69363-14-0 | COA |
| BCN1024 |
Schisantherin A
|
58546-56-8 | COA |
| BCN1023 |
Schisantherin B
|
58546-55-7 | COA |
| BCN6766 |
Schisantherin E
|
64917-83-5 | COA |
| BCN3315 |
Schisanwilsonin H
|
1181216-83-0 | COA |
| BCN5548 |
Schisanwilsonin I
|
1181216-84-1 | COA |
| BCN1021 |
Schizandrin A
|
61281-38-7 | COA |
| BCN1022 |
Schizandrin B
|
61281-37-6 | COA |
| BCN5808 |
Wulignan A1
|
117047-76-4 | COA |
References
[Optimization of Aqueous Two-Phase Extraction of Polysaccharide from Schisandra chinensis Using Response Surface Methodology with Box-Behnken Design].[Pubmed: 30091354]
To optimize the extraction condition of polysaccharide from Schisandra chinensis. Aqueous two-phase extraction( ATPE) method was used, based on Box-Behnken design with Response surface methodology( BBD-RSM).
Protective effects of Schisandrin on high glucose-induced changes of RhoA and eNOS activity in human umbilical vein endothelial cells.[Pubmed: 30031586]
Schisandrin, derived from the Chinese medicinal herb Schisandra chinensis, has been found to confer protective effects on circulation systems. But the underlying molecular mechanisms remain unclear. The aim of this study was to investigate the effects of a high level of glucose on RhoA and eNOS activity in human umbilical vein endothelial cells(HUVECs) and how Schisandrin plays a role in mediating these effects. To find the optimal treatment time, HUVECs were cultured at a high glucose concentration (30 mM) for different lengths of time (0, 12, 24, and 48 h). Subsequently, the cells were randomized into five groups: a normal group, a high glucose group, and three high glucose groups that were given different doses (5, 10, and 20 μM) of Schisandrin. The cells were pretreated with Schisandrin for 24 h before stimulation with high glucose. The morphology of HUVECs in the various groups was assessed under a light microscope. Immunocytochemical staining was used to detect the level of p-MYPT1 expression. The levels of RhoA activity were determined using the RhoA Activation Assay Biochem Kit. The levels of eNOS activity were examined using a nitrate reduction test. The results showed that in the high glucose group, the activity of RhoA was increased and the activity of eNOS was reduced, thus decreasing the secretion of NO. However, after pretreatment with Schisandrin (10, 20 μM), the activity of RhoA was inhibited and the activity of eNOS increased, which led to an increase in NO production compared with the high glucose group. There was no evident difference between the 5 μM Schisandrin group and the high glucose group. Taken together, these findings indicate that Schisandrin can improve the function of endothelial cells by lowering the activity of RhoA/Rho kinase and raising both the activity of eNOS and the production of NO.
